According to reports from NDTV Profit, Torrent Pharmaceuticals Ltd. delivered Q4 FY26 consolidated results that came in ahead of brokerage estimates, largely aided by the consolidation of JB Pharma from January 21, 2026. The standalone/base business performance remained broadly in line with estimates, as reported by NDTV Profit. Excluding JB Pharma, Torrent delivered 16% YoY revenue growth with Ebitda margin sustained at 32.7%, supported by continued strong traction across key branded markets.
As reported by NDTV Profit, the India business outperformed the IPM led by chronic therapies, Curatio scale-up and early success in semaglutide launches. The Brazil business maintained healthy momentum driven by new launches and pricing actions, while the US business continued to recover aided by recent launches and improved offtake from existing products. These performance metrics demonstrate Torrent's diversified geographic presence and operational strength across key markets.
According to NDTV Profit, the JB Pharma acquisition strengthens Torrent's India franchise and medium-term growth visibility. However, as noted by Nirmal Bang, current valuations largely factor in the near-term earnings and synergy benefits from this strategic acquisition. The brokerage maintains that while the deal enhances Torrent's market position, the market pricing already reflects these positive developments.
As reported by NDTV Profit, domestic brokerage firm Nirmal Bang has maintained Hold rating on Torrent Pharmaceuticals Ltd. with a target price of ₹4,898, valuing the company at 24x FY28E EV/Ebitda. This target price implies a ~10% premium to its five-year average multiple, suggesting that while the company shows strong operational performance, current market valuations adequately reflect its growth prospects and strategic positioning. While the JB Pharma acquisition strengthens Torrent's India franchise and medium-term growth visibility, current valuations largely factor in the near-term earnings and synergy benefits.
